CRISPR's Mixed Bag: A Glimpse into Gene Editing's Uncertain Future CRISPR Therapeutics AG, a pioneering gene editing firm, has released its Q1 2026 results, which are mixed at best.
The company reduced its net loss by $13 million compared to last year, a welcome sign in an industry plagued by high R&D expenses.
However, revenue from its CASGEVY treatment, while respectable with over 500 patients worldwide, still lags behind expectations. A closer examination of CRISPR's financials reveals disturbing trends.